Generex AE37 Prostate Cancer Vaccine Part of Recent Study

Generex AE37 Prostate Cancer Vaccine Part of Recent Study
Generex Biotechnology Corporation, a company focused on the research and development of drug delivery systems and technologies, has announced a follow-up study from its Phase I clinical trial of the immunotherapeutic agent AE37 in patients with prostate cancer. Prostate cancer is the second most common cancer in men worldwide, and the 6th leading cause of cancer-related death.

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *